Veru (VERU) Stock Price, News & Analysis

Company Overview

Veru Inc. is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19. In parallel, Veru is developing toremifene, a selective estrogen receptor modulator repurposed to address chemotherapy-induced side effects and support women’s health applications. The company’s pipeline also encompasses exploratory programs aimed at targeting key drivers of cancer progression and acute inflammatory responses.

Founded in 2010 (formerly operating as Veru Healthcare) by Dr. Mark A. Enyedy, who serves as President and Chief Executive Officer, Veru has conducted clinical studies across North America, Europe and Asia. The company maintains collaborations with academic institutions and contract research organizations to execute multi-center trials, and it has secured manufacturing partnerships to support planned commercial supply. Veru’s leadership team combines expertise in pharmaceutical development, regulatory affairs and oncology drug commercialization to guide late-stage program advancement.

Key Stats

• Today's Range: $2.69 to $2.83
• 50-Day Range: $2.21 to $4.23
• 52-Week Range: $2.05 to $7.33
• Volume: 454,272 shs
• Average Volume: 297,005 shs
• Market Capitalization: $44.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.00
• Consensus Rating: Moderate Buy

Veru Stock Analysis - MarketRank™

Veru scored higher than 51% of companies evaluated by MarketBeat, and ranked 644th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Veru has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Veru has a consensus price target of $23.00, representing about 724.4% upside from its current price of $2.79.

Amount of Analyst Coverage

Veru has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Veru are expected to decrease in the coming year, from ($1.07) to ($1.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Veru is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Veru is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Veru has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.07% of the float of Veru has been sold short.

Short Interest Ratio / Days to Cover

Veru has a short interest ratio ("days to cover") of 6.6.

Change versus previous month

Short interest in Veru has recently decreased by 1.31%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veru does not currently pay a dividend.

Dividend Growth

Veru does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.89

News Sentiment

Veru has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Veru this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for VERU on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Veru to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Veru insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.20% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

47.16% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 8/11/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:VERU
• CIK: 863894
• Web: www.veruhealthcare.com
• Phone: (305) 509-6897
• Fax: 312-595-9122
• Employees: 230
• Year Founded: 1896

Price Target and Rating

• Average Price Target for Veru: $23.00
• High Price Target: $25.00
• Low Price Target: $20.00
• Potential Upside/Downside: +724.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.73 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -46.91%
• Return on Assets: -35.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.19
• Quick Ratio: 6.19

Sales & Book Value

• Annual Sales: $16.89 million
• Price / Sales: 2.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.25 per share
• Price / Book: 2.23

Miscellaneous

• Outstanding Shares: 16,050,000
• Free Float: 13,771,000
• Market Cap: $44.78 million
• Optionable: Optionable
• Beta: -1.15